3.24
+0.01(+0.31%)
Currency In USD
| Previous Close | 3.23 |
| Open | 3.17 |
| Day High | 3.33 |
| Day Low | 3.13 |
| 52-Week High | 4.89 |
| 52-Week Low | 1.05 |
| Volume | 1.37M |
| Average Volume | 1.8M |
| Market Cap | 351.04M |
| PE | -2.05 |
| EPS | -1.58 |
| Moving Average 50 Days | 3.24 |
| Moving Average 200 Days | 2.16 |
| Change | 0.01 |
If you invested $1000 in Aclaris Therapeutics, Inc. (ACRS) 10 years ago, it would be worth $193.32 as of February 21, 2026 at a share price of $3.24. Whereas If you bought $1000 worth of Aclaris Therapeutics, Inc. (ACRS) shares 5 years ago, it would be worth $140.69 as of February 21, 2026 at a share price of $3.24.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aclaris Therapeutics to Participate in Two February Healthcare Conferences
GlobeNewswire Inc.
Feb 04, 2026 12:00 PM GMT
WAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company wi
Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)
GlobeNewswire Inc.
Jan 27, 2026 11:55 AM GMT
- ATI-2138 Outperforms Ritlecitinib in Reversal Model of Alopecia Universalis, the Most Severe AA Phenotype - WAYNE, Pa., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focuse
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052
GlobeNewswire Inc.
Jan 12, 2026 11:55 AM GMT
WAYNE, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiat